文献速递类风湿关节炎

早期类风湿关节炎滑膜细胞与分子特征分层预测csDMARD治疗反应及影像学进展

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.
PubMed 文献 · Ann Rheum Dis · 2019-03-16

该研究对144例未经治疗的早期RA患者(症状持续时间<12个月)在DMARD启动前及6个月后行超声引导下滑膜活检,通过免疫组化和NanoString分析滑膜细胞与分子特征。研究发现三种滑膜病理类型:淋巴-髓系型、弥漫-髓系型和寡免疫型,其分子特征与疾病活动度、DMARD反应及12个月影像学进展相关。

要点

  • 早期RA滑膜存在三种病理类型:淋巴-髓系型、弥漫-髓系型和寡免疫型。
  • 髓系和淋巴系相关基因表达升高与疾病活动度、急性期反应物及6个月DMARD反应强相关。
  • 滑膜淋巴系相关基因升高与自身抗体阳性相关,破骨细胞靶向基因升高预测12个月影像学关节损伤进展。

核心结论

  • 在治疗前早期RA滑膜中即存在特定细胞/分子特征,可区分疾病严重程度/进展及治疗反应。

研究设计与样本

  • 144例连续未经治疗的早期RA患者(症状持续时间<12个月)在DMARD启动前及6个月后行超声引导下滑膜活检。
  • 滑膜活检进行细胞(免疫组化)和分子(NanoString)特征分析,并与临床和影像学结局比较。

主要发现

  • 滑膜细胞和分子分析首次在早期RA中显示三种病理类型:淋巴-髓系型(B细胞加髓系细胞)、弥漫-髓系型(髓系为主但B细胞少)和寡免疫型(免疫细胞稀少、基质细胞为主)。
  • 髓系和淋巴系相关基因表达升高与疾病活动度、急性期反应物及6个月DMARD反应强相关。
  • 滑膜淋巴系相关基因升高与自身抗体阳性相关,破骨细胞靶向基因升高预测12个月影像学关节损伤进展。
  • 以寡免疫病理为主的患者疾病活动度和影像学进展较轻。

临床怎么用

  • 滑膜细胞/分子特征可能有助于在治疗前识别早期RA患者的疾病严重程度、进展风险及治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To unravel the hierarchy of cellular/molecular pathways in the disease tissue of early, treatment-naïve rheumatoid arthritis (RA) patients and determine their relationship with clinical phenotypes and treatment response/outcomes longitudinally. METHODS: 144 consecutive treatment-naïve early RA patients (<12 months symptoms duration) underwent ultrasound-guided synovial biopsy before and 6 months after disease-modifying antirheumatic drug (DMARD) initiation. Synovial biopsies were analysed for cellular (immunohistology) and molecular (NanoString) characteristics and results compared with clinical and imaging outcomes. Differential gene expression analysis and logistic regression were applied to define variables correlating with treatment response and predicting radiographic progression. RESULTS: Cellular and molecular analyses of synovial tissue demonstrated for the first time in early RA the presence of three pathology groups: (1) lympho-myeloid dominated by the presence of B cells in addition to myeloid cells; (2) diffuse-myeloid with myeloid lineage predominance but poor in B cells nd (3) pauci-immune characterised by scanty immune cells and prevalent stromal cells. Longitudinal correlation of molecular signatures demonstrated that elevation of myeloid- and lymphoid-associated gene expression strongly correlated with disease activity, acute phase reactants and DMARD response at 6 months. Furthermore, elevation of synovial lymphoid-associated genes correlated with autoantibody positivity and elevation of osteoclast-targeting genes predicting radiographic joint damage progression at 12 months. Patients with predominant pauci-immune pathology showed less severe disease activity and radiographic progression. CONCLUSIONS: We demonstrate at disease presentation, prior to pathology modulation by therapy, the presence of specific cellular/molecular synovial signatures that delineate disease severity/progression and therapeutic response and may pave the way to more precise definition of RA taxonomy, therapeutic targeting and improved outcomes.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Humby F, Lewis M, Ramamoorthi N, et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann Rheum Dis. 2019. PMID: 30878974. doi:10.1136/annrheumdis-2018-214539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。